106
Participants
Start Date
November 14, 2014
Primary Completion Date
December 21, 2022
Study Completion Date
December 22, 2022
BMS-986012 (anti-fucosyl-GM1)
Nivolumab
Local Institution - 0020, St Leonards
Local Institution - 0002, Clayton
Local Institution - 0012, Liège
Local Institution - 0011, Brisbane
Local Institution - 0015, Ghent
Local Institution - 0004, New York
Local Institution - 0021, Winston-Salem
Local Institution - 0001, Durham
Local Institution - 0003, Edmonton
Local Institution - 0017, Halifax
Local Institution - 0019, Hamilton
Local Institution - 0010, London
Local Institution - 0007, Toronto
Local Institution - 0013, Nijmegen
Local Institution - 0009, San Juan
Local Institution - 0008, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY